What is AtriCure?
Founded in 2000 and headquartered in Mason, Ohio, AtriCure operates at the intersection of advanced engineering and clinical medicine. The company specializes in the development of innovative surgical and non-surgical solutions designed to address the complexities of Afib. By focusing on high-precision medical devices, AtriCure has established itself as a key player in the electrophysiology market. Its market position is defined by a commitment to improving patient outcomes through technological advancements that simplify complex cardiac procedures, thereby reducing the burden on healthcare providers and improving long-term patient health metrics.
How much funding has AtriCure raised?
AtriCure has raised a total of $70.8M across 2 funding rounds:
Other Financing Round
$21M
Stock Offering
$49.8M
Other Financing Round (2002): $21M with participation from New England Partners, Camden Partners, Charter Venture Group, Partisan Management Group, U.S. Venture Partners, and Foundation Medical Partners
Stock Issuance/Offering (2005): $49.8M led by Undisclosed
Key Investors in AtriCure
U.S. Venture Partners
U.S. Venture Partners is a prominent Silicon Valley venture capital firm that collaborates with entrepreneurs to develop transformative companies, with a strong focus on healthcare and enterprise software.
Camden Partners
Camden Partners Growth Equity specializes in growth equity investments in lower middle market companies, utilizing a thematic approach to support software and technology-enabled business services.
Foundation Medical Partners
Foundation Medical Partners is an investment entity focused on the hospitals and physicians clinics industry, providing essential capital to support clinical innovation.
What's next for AtriCure?
Looking ahead, the infusion of capital positions AtriCure to accelerate its research and development pipeline, focusing on the next generation of ablation technologies. The company is expected to leverage this strategic financing to enhance its commercial infrastructure and deepen its penetration into international markets. As the demand for minimally invasive cardiac interventions continues to rise, AtriCure is well-positioned to capitalize on its intellectual property portfolio. The firm's strategic roadmap likely includes further clinical validation studies and the potential for synergistic acquisitions to maintain its competitive edge in the rapidly evolving medical device industry.
See full AtriCure company page
